MELBOURNE (Reuters) - The National Institutes of Health (NIH) is set to launch a large trial using antibodies to test a way to prevent birth defects, such as blindness and deafness, caused by mothers passing a common virus to their unborn babies. Australian blood plasma group CSL said on Thursday it would donate $2.5 million worth of cytomegalovirus (CMV) antibodies from human plasma to the NIH for the trial in the United States. Analysis of the trial is expected in 2016. There is no vaccine available yet to prevent CMV infection, the most common infection that causes birth defects. ... read more..